Finding Description
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** d. Resident #87 was readmitted to the facility on [DATE], with diagnoses which included dementia, urinary issues, and cardiac issues.
A Quarterly MDS assessment, dated 9/29/18, documented Resident #87 had severe cognitive impairment.
Resident #87's physician orders, dated 11/7/18, documented his medication duloxetine (a medication used to treat depression and pain) was increased from 20 mg orally every day to 60 mg each day.
Resident #87's current care plan documented he experienced pain, difficulty concentrating, fear of others causing him harm, and changes in sleep patterns. Resident #87's care plan lacked specific behaviors staff were to monitor Resident #87 for and lacked interventions related to the use of the psychoactive medication, duloxetine.
On 11/8/18 at 1:25 PM, the Pharmacist confirmed the facility failed to develop and implement a resident specific care plan that described resident specific behaviors and included inventions related to Resident #87's use of duloxetine.
On 11/8/18 at 10:44 AM, the DON stated she looked for resident specific behaviors and where they may be located. The DON stated residents' sleep habits were evaluated in the GDR meetings verbally and a resident's behaviors were discussed. The DON stated the current GDR form did not document the conversation that took place for the residents.
On 11/9/18 at 10:19 AM, LMSW #1 stated he received alerts from staff when a resident was experiencing increased behaviors and the GDR committee evaluated trends from the alerts. LMSW #1 stated the CNA Behavior Monitoring flowsheets did not include hallucinations and delusions, but staff documented these in the MDS and throughout the progress notes when they were seen by staff. LMSW #1 stated psychotropic medications could increase a resident's fall risk and the facility did not provide PRN psychotropic medications when a 1:1 staff member was unavailable. LMSW #1 stated staff provided the PRN medications when a resident exhibited behaviors. LMSW #1 stated the specific behavior the resident exhibited should be documented in their clinical record for any PRN psychotropic medication administered. LMSW #1 stated the care plan should identify resident specific behaviors for dementia, hallucinations, and delusions and if they were harmful. LMSW #1 stated the current behavior monitors were helpful with gathering information in addition to the alerts he received and the MDS.
On 11/9/18 at 12:23 PM, the DON stated according to the care plan Resident #261 was to have a 1:1 staff member with him on 5/26/18. The DON stated he may have been provided a 1:1 for short durations before that. The DON stated the facility would not provide PRN psychotropic medications when a 1:1 staff member was unavailable, only when residents' behaviors increased. The DON stated the behavior monitors were not resident specific and the staff documented specific instances throughout the progress notes. The DON stated in the GDR meeting the team reviewed each residents' behaviors and evaluated items such as sleep, and what the team discussed was documented in the GDR note
Based on observation, staff interview, record review, and facility policy review, it was determined the facility failed to a) attempt GDR of psychotropic medications, b) monitor behavioral symptoms, c) obtain informed consents for the medications, and d) identify resident specific behaviors on the care plan. This was true for 4 of 6 residents (#2, #30, #87, and #261) reviewed for unnecessary medications. This resulted in harm to Resident #261 when he experienced increased somnolence, sedation, and a decline in ADL's as a result of multiple psychotropic medications. This deficient practice also had the potential for harm of other residents if they receive unnecessary psychotropic medications which were not adequately monitored. Findings include:
A facility policy Mood and Behavior Medication Review Committee, undated, documented the committee identified and evaluated residents use of medication for behaviors or mood and the committee would determine the appropriate interventions and ensure consents, orders, and care plans were completed.
The facility's ADL Behavior Monitor flowsheets documented the following behaviors for every resident in the facility, wandering, verbal abusive, physical abusive, socially inappropriate behavior, resistive or rejection of care.
The facility's ADL Mood Symptoms Monitor flowsheets documented the following behavior for every resident in the facility, little interest or pleasure in doing things, feeling or appearing down/ depressed, trouble falling asleep or staying asleep, feeling tired, poor appetite or overeating, feeling bad about themselves, trouble concentrating, moving extremely slow and speaking slow so that others notice, suicidal ideation, and short tempered. The facility did not have resident specific behaviors for staff to monitor.
a. Resident #261 was admitted to the facility on [DATE], with diagnoses including dementia with Lewy bodies (abnormal protein deposits in the brain) and behavioral disturbances, depression, and sleep disorder.
A significant change MDS assessment, dated 6/7/18, documented Resident #261 was severely cognitively impaired and he was totally dependent or required extensive assistance from one to two staff members with cares. The MDS documented Resident #261 had signs and symptoms of mild depression and he exhibited delusions and hallucinations. The MDS documented Resident #261 had physical, verbal, and other behaviors 4-6 days a week. The MDS documented he did not wander or reject cares.
i. Resident #261's May 2018 Physician Orders included the following scheduled and PRN medications:
Scheduled Medications:
- Depakote (anticonvulsant) 500 mg by mouth one time a day for Lewy bodies dementia with hallucinations and agitation, ordered on 5/31/18 and discontinued the same day.
- Remeron (antidepressant) 15 mg at bedtime for depression and insomnia, ordered on 4/2/18 and discontinued on 6/1/18.
- Seroquel (antipsychotic) 200 mg at bedtime for dementia with hallucinations, ordered on 4/24/18 and discontinued on 5/23/18.
- Seroquel 100 mg two times a day for dementia with hallucinations, ordered on 4/27/18 and discontinued on 5/23/18.
- Seroquel 300 mg at bedtime for dementia with hallucinations, ordered on 5/23/18 and discontinued on 5/31/18.
- Topamax (anticonvulsant) 25 mg at bedtime for unstable mood, ordered on 3/30/18 and discontinued on 6/12/18.
- Zoloft (antidepressant) 200 mg one time a day for depression, ordered on 3/30/18 and discontinued on 6/1/18.
PRN Medications:
- Ativan (sedative and antianxiety) 1 mg intramuscularly (IM) one time only for extreme anxiety, ordered on 5/9/18.
- Ativan 1 mg IM one time only for Lewy bodies dementia related to delirium, ordered on 5/23/18.
- Ativan 1 mg IM one time only for Lewy bodies dementia related to delirium, ordered on 5/24/18.
- Ativan 0.5 mg IM one time only for extreme anxiety, ordered on 5/27/18.
- Ativan 1 mg intramuscularly every 24 hours PRN for agitation, ordered on 5/31/18 and discontinued on 6/4/18.
- Oxycodone (narcotic) 5 mg every 6 hours PRN for pain, ordered on 5/21/18 and discontinued on 6/12/18.
- Seroquel 100 mg one time only for dementia with hallucinations, ordered on 5/23/18.
- Trazadone (sedative and antidepressant) 25 mg every 8 hours PRN for anxiety, ordered on 4/2/18 and discontinued on 5/23/18.
- Trazadone 50 mg every 8 hours PRN for anxiety, ordered on 5/23/18 and discontinued on 6/12/18.
Resident #261 received 2 antidepressant medications, Remeron and Zoloft, daily from 4/2/18 to 6/1/18, and 1 antipsychotic medication, Seroquel, daily from 4/24/18 to 5/31/18. Two medications, Seroquel and Depakote, were prescribed for hallucinations according to the MAR documentation. He also had orders for 2 antianxiety medications PRN, Ativan and Trazadone. Additionally, the medications Seroquel, Remeron, Trazadone, Ativan, and Oxycodone had sedative effects.
Resident #261's June 2018 Physician Orders included the following scheduled and PRN medications:
Scheduled Medications:
- Ativan 1 mg/ml by mouth three times a day for agitation, ordered on 6/5/18 and discontinued on 6/6/18.
- Ativan 1 mg/ml by mouth two times a day for agitation, ordered on 6/6/18 and discontinued the same day.
- Ativan 1 mg/ml by mouth every eight hours for agitation, ordered on 6/6/18 and discontinued on 6/14/18.
- Clonazepam (antianxiety) 0.5 mg by mouth two times a day for comfort and seizure control, ordered on 6/1/18 and discontinued on 6/6/18.
- Depakote extended release 500 mg by mouth at bedtime for Lewy bodies dementia with hallucinations and agitation, ordered on 6/1/18 and discontinued on 6/12/18.
- Seroquel 50 mg two times a day for dementia with hallucinations, ordered on 5/23/18 and discontinued on 6/12/18.
- Seroquel 200 mg at bedtime for dementia with hallucinations, ordered on 5/31/18 and discontinued on 6/12/18.
- Topamax 25 mg at bedtime for unstable mood, ordered on 3/30/18 and discontinued on 6/12/18.
PRN Medications:
- Ativan 0.5 mg by mouth every 2 hours PRN for agitation, ordered on 6/1/18 and discontinued on 6/5/18.
- Ativan 0.5 mg by mouth every hour PRN for agitation, ordered on 6/5/18 and discontinued on 6/14/18.
- Ativan 1 mg IM every 24 hours PRN for agitation, ordered on 5/31/18 and discontinued on 6/4/18.
- Ativan 1 mg IM every 24 hours PRN for agitation, ordered on 6/4/18 and discontinued on 6/14/18.
- Morphine Sulfate (narcotic) 10 mg sublingually every 2 hours PRN for pain and air hunger, ordered on 6/1/18 and discontinued on 6/14/18.
- Oxycodone 5 mg every 6 hours PRN for pain, ordered on 5/21/18 and discontinued on 6/12/18.
- Trazadone 50 mg every 8 hours PRN for anxiety, ordered on 5/23/18 and discontinued on 6/12/18.
Resident #261's antidepressants, Remeron and Zoloft, were discontinued and he had 2 antianxiety medications added to be taken daily, Ativan and Clonazepam. He also had PRN orders for Ativan, and a new order for Morphine Sulfate for pain. Additionally, the medications Ativan, Clonazepam, Seroquel, Morphine Sulfate, Oxycodone, and Trazadone had sedative effects.
ii. Resident #261's 5/1/18 through 6/14/18 MAR documented he was administered a PRN psychotropic medication, Trazadone or Ativan, within 0 to 15 minutes of a PRN pain medication, Oxycodone or Morphine, being administered. Examples include:
- Oxycodone and Trazadone were administered together on 5/23/18 at 2:25 PM and 10:06 PM, 5/24/18 at 3:45 PM, 5/30/18 at 12:33 AM, and 6/4/18 at 3:30 AM.
- Oxycodone and Ativan were administered together on 6/2/18 at 1:12 PM, 6/3/18 at 10:45 AM, and 6/5/18 at 3:03 PM.
- Morphine and Trazadone were administered together on 6/6/18 at 4:00 AM.
- Morphine and Ativan were administered together on 6/1/18 at 1:30 PM, 6/3/18 at 1:40 PM, 6/3/18 at 4:10 PM, 6/4/18 at 6:30 AM, 9:35 AM, and 12:15 PM, 6/6/18 at 3:07 PM, 5:07 PM, and 9:15 PM, 6/10/18 at 10:01 PM, 6/11/18 at 3:32 PM, and 6/12/18 at 1:50 PM.
According to the Nursing 2019 Drug Handbook, Ativan by IM injection takes 15-30 minutes to take effect and when given orally it takes 1 hour. Additionally, the Nursing 2019 Drug Handbook stated Ativan, Trazadone, and Oxycodone side effects include sedation, confusion, insomnia, dizziness, and drowsiness.
This occurred 21 times on 12 days, from 5/23/18 to 6/12/18. The staff did not allow adequate time for the pain medication or the antianxiety medication administered to take effect. It was unclear if Resident #261 was anxious or in pain. According to the Nursing 2018 Drug Handbook the side effects for Ativan, Trazadone, Oxycodone, and Morphine Sulfate included sedation, confusion, insomnia, dizziness, and drowsiness.
The progress notes for Resident #261 for the above listed dates and times included documentation he received Ativan or Trazadone PRN for agitation and/or anxiety. The progress notes did not include documentation of how Resident #261's agitation and/or anxiety presented or specific behaviors related to his agitation and/or anxiety.
iii. Resident #261's May 2018 Behavior flowsheet documented he experienced the following behaviors:
- Wandering- 3 episodes on 5/6/18, 5/17/18, and 5/20/18
- Physically abusive- 1 episode on 5/21/18
- Resistive or rejection of care- 2 episodes on 5/22/18 and 5/23/18
Resident #261's 6/1/18 through 6/13/18 Behavior flowsheet documented he experienced the following behaviors:
- Physically abusive- 1 episode on 6/3/18
- Resistive or rejection of care- 1 episodes on 6/2/18
Resident #261's progress notes did not correlate with his Behavior Monitoring flowsheets for May and June of 2018. Examples include:
- A Progress note, dated 5/14/18 at 9:39 PM, documented Resident #261 was agitated and continued to ambulate without his wheelchair or assistance and a PRN Trazadone was provided at 2:53 PM. The note documented Resident #261 needed 1:1 staff supervision from 1:00 PM to 9:00 PM and a light duty staff member was only available from 4:00 PM to 6:00 PM. Resident #261's care plan was not updated to include the need for 1:1 staff supervision on 5/14/18, and it was unclear if he was to have a 1:1 CNA present for the duration of time between 1:00 PM and 9:00 PM.
- Progress Notes, dated 5/23/18 at 2:25 PM, documented Resident #261 was provided a PRN Trazadone for anxiety and calling out and excessive movement in his wheelchair, PRN Oxycodone for pain, and Seroquel was given early to help with calming anxiety. There was no documentation of Resident #261 calling out or other behaviors related to anxiety in the behavior monitor flowsheet. Additionally, the progress note did not include a description how his anxiety presented.
A subsequent Progress Note, at 11:05 PM on 5/23/18, documented Resident #261 woke up at 8:50 PM and was combative, agitated, and refused his bedtime medications by spitting them out at the nurse. The note documented Resident #261 was also kicking and hitting the nurse and CNAs. Resident #261 refused drink and food and was assisted to the common area to sit in a recliner for better observation by staff. The note documented he required 1:1 supervision because Resident #261 attempted to transfer himself and was constantly repositioning himself in the recliner. The note documented Resident #261 was anxious during most of the shift and rested for a few hours after dinner while his 1:1 supervision CNA was with him. The note documented IM Ativan was not initially effective and PRN Trazadone, Oxycodone, and Seroquel were administered to help settle his delirium/anxiety.
The note did not include a description of how Resident #261 presented with delirium or anxiety. The Behavior Monitoring flowsheet documented Resident #261 was resistive to cares, there was no documentation related to his delirium, anxiety, or hitting and kicking at staff.
The MAR documented he was administered a PRN dose of Ativan IM at 9:53 PM and at 10:06 PM, 13 minutes later, he was administered a dose of PRN Trazadone and PRN Oxycodone. At 10:13 PM, 7 minutes later, he was administered a dose of PRN Seroquel. The staff did not provide adequate time for the antianxiety medication to take effect before administering another 2 psychotropic medications and a pain medication.
- A Progress Note, dated 5/24/18 at 10:53 PM, documented Resident #261 was pleasant and cooperative for most of the shift. The note documented he was administered a PRN pain and antianxiety medication for an increase in symptoms/suspected pain, with successful result. The note documented at 6:45 PM, Resident #261 was restless, yelled and hit staff, and attempted to self-transfer out of his chair, and his scheduled Remeron, Seroquel, and Topamax did not decrease his anxiety. The note documented the physician ordered a one-time dose of IM Ativan which was given and he calmed down afterwards and was observed sleeping in a recliner chair. There was no documentation in his Behavior Monitoring flowsheet Resident #261 hit staff or he exhibited other behaviors.
- A Progress Note, dated 5/27/18 at 3:00 AM, documented Resident #261 woke up and he was calling out he wanted to use the bathroom and go home. Resident #261 was unable to stand up and comprehend instructions with using the mechanical lift and required 3 CNAs to assist with the transfer. He was given a dose of PRN Trazadone related to anxiety, which was ineffective. Resident #261 was moved to the nurses' station and continued to call out. The note documented a 1:1 sitter was not available for the night shift and a staff member assigned to a different unit volunteered to assist as Resident #261's 1:1 for 1-2 hours. Resident #261 was administered a PRN IM Ativan dose at 3:22 AM. There was no documentation describing how Resident #261's anxiety presented.
- A Progress Note, dated 6/4/18 at 10:41 AM, documented Resident #261 had increased confusion and was restless and picked up unseen items on the floor. The note documented he had a change in his previous normal pattern of behavior with an increase in negative behaviors and increased confusion and agitation. Resident #261's 6/4/18 MAR documented he was administered a dose of PRN Ativan and PRN Morphine at 12:15 PM, a dose of PRN Trazadone at 2:00 PM, and a dose of PRN IM Ativan at 2:40 PM. The Behavior Monitoring flowsheet did not include documentation of behaviors or an increase in behaviors. There was also no documentation in the Behavior Monitoring flowsheet about how Resident #261 exhibited agitation.
iv. Resident #261's care plan did not include specific behaviors and did not identify or include depression and anxiety.
Resident #261's care plan addressed cognition, dated 3/27/18, and documented he had impaired cognition related to Lewy body dementia and was rarely understood and had difficulty understanding. The care plan did not document how his dementia presented.
Resident #261's care plan area addressed elopement risk, dated 4/13/18, and documented he verbalized wanting to leave the facility and wandered the facility. Interventions included Resident #261 had a roam alert bracelet on his wheelchair, dated 4/13/18, and staff were to provide 1:1 supervision until Resident #261 stopped attempting to leave the facility, dated 5/26/18. The care plan did not include identification of behaviors associated with the 1:1 intervention initiated on 5/26/18.
The care plan area addressing Resident #261's behaviors and mood, dated 6/28/17, documented he was cognitively impaired and had dementia. The care plan documented he had behavioral issues with hallucinations and delusions. The care plan documented Resident #261 had suicidal ideation, hit staff, and screamed.
Resident #261's care plan did not identify if Resident #261's hallucinations and or delusions were tactile [touch], visual, auditory, and olfactory [smell]), was not resident specific and did not document clearly how his hallucinations or delusions presented. The care plan did not document if his hallucinations or delusions were harmful to him.
Resident #261 did not have a care plan for his anxiety or his depression. The facility did not identify how Resident #261's anxiety, agitation, or depression presented.
v. Resident #261's MAR and Progress Notes documented his hours of sleep increased as medications were added.
The care plan area addressing Resident #261's sleep cycle, dated 6/19/17, documented he was taking medications daily to assist him with sleep. The care plan documented staff were to monitor Resident #261's hours of sleep at night and staff were to encourage him to maintain his home routine of going to bed at 8:00 PM and waking at 6:00 AM.
Resident #261's May 2018 MAR documented he was sleeping from 3 hours to 16 hours a day and averaged 9 hours daily. Examples include:
- On 5/2/18, the MAR documented he slept 11 hours. A progress note, dated 5/2/18, documented Resident #261 was administered a PRN Trazadone as he was unable to sleep and settle down. Resident #261's Trazadone was ordered for anxiety, not sleep.
- Resident #261's MAR documented he slept 9 hours during the 5/8/18 evening shift.
- Resident #261's MAR documented for the night shift on 5/23/18 he slept 7 hours, and during the day shift on 5/24/18 he slept for 4 hours.
- Resident #261's MAR documented for the night shift on 5/27/18 he slept 7 hours, and during the day shift on 5/28/18he slept for 4 hours.
- Resident #261's MAR documented he slept for 10 hours on 5/29/18, on 5/30/18 he slept 7 hours, and on 5/31/18 he slept 10 hours during the 24 hour period.
Resident #261's June 2018 MAR documented he was sleeping from 7 to 24 hours a day and averaging 15 hours daily. Examples include:
- Resident #261's Sleep Monitor flowsheet for 6/4/18 documented he slept 8 hours during the 24 hour period.
- Resident #261's Sleep Monitor flowsheet for 6/5/18 documented he slept 9 hours during the 24 hour period.
- Resident #261's Sleep Monitor flowsheet for 6/6/18 documented he slept 16 hours during the 24 hour period.
- Resident #261's Sleep Monitor flowsheet documented he slept 11 hours on 6/7/18, 16 hours on 6/8/18, 21 hours on 6/9/18, 16 hours on 6/10/18, 21 hours on 6/11/18, and 24 hours on 6/12/18 and 6/13/18.
vi. Resident #261's GDR did not review specific behaviors or evaluate his sleeping habits.
Resident #261's Quarterly GDR review, dated 6/6/18, documented Resident #261 was on Ativan, Trazadone, Seroquel, and Depakote. The GDR review documented he was on these medications for sleep and behavioral disturbances with Lewy Body Dementia. The review documented Resident #261 had hallucinations, increased paranoia, and was on hospice and the committee recommended no changes to his medication regime.
The review did not evaluate Resident #261 for how many episodes/behaviors of hallucinations, depression, and or anxiety he experienced during the look back period. The GDR review did not include an evaluation of the increase in the hours he slept. The review did not include an evaluation what his hallucination or paranoia looked like or identify what other behaviors he was experiencing and how they were harmful to him.
On 11/9/18 at 10:19 AM, LMSW #1 stated Resident #261 was actively delusional and paranoid of people trying to do bad to him. LMSW #1 stated the medications were being managed by a Psychiatrist and he experienced hallucinations as well.
b. Resident #30 was readmitted to the facility on [DATE], with diagnoses including dementia.
A quarterly MDS assessment, dated 8/13/18, documented Resident #30 was severely cognitively impaired and had no signs and symptoms of depression. The MDS documented he did not exhibit inappropriate behaviors, hallucinations, delusions, rejection of cares, or wandering.
Resident #30's October 2018 Physician Orders included:
- Zyprexa 5 mg by mouth in the afternoon and evening for dementia, ordered 10/22/18.
- Trazadone 100 mg at bedtime for insomnia, ordered 4/2/18.
- Trazadone 25 mg in the afternoon for anxiety, ordered 10/19/18.
- Oxycodone 5 mg twice daily for arthritis pain, ordered 9/28/18.
The care plan area addressing Resident #30's sleep cycle, dated 3/9/17, documented he was taking medications daily to assist him with sleep. The care plan documented staff were to monitor Resident #30's hours of sleep at night.
The care plan area addressing Resident #30's behaviors/cognition, revised 5/23/18, documented he was cognitively impaired and had dementia. The care plan documented Resident #30 was angry and frustrated at times. It did not specifically describe how Resident #30's dementia presented.
Resident #30's care plan did not include specific goals and interventions related to his anxiety and did not describe how his anxiety presented.
Resident #30's Quarterly GDR review, dated 9/13/18, documented Resident #30 was receiving Zyprexa and Trazadone. The GDR review documented he was taking the medications for sleep and dementia. The review documented Resident #30 had poor safety awareness and had several falls. The review documented he exhibited anxiety by leaning forward in his Broda chair. The review documented the committee recommended decreasing Resident #30's Zyprexa to 5 mg in the afternoon and 2.5 mg before bed. This was completed and then the medication was increased back to 5 mg twice daily on 10/29/18, when the physician discontinued another psychotropic medication (Lexapro, an antidepressant). Resident #30's GDR did not include a review of specific behaviors or evaluate his sleeping habits.
Resident #30's 8/1/18 through 11/7/18 Behavior Monitoring flowsheets documented he did not exhibit behaviors. The review did not evaluate the number of behaviors and/or symptoms of anxiety Resident #30 experienced during the look back period, to assess the ongoing need for the medications.
Resident #30's 10/1/18 through 11/6/18 MAR documented he was sleeping from 11 to 21 hours a day and averaging 16 hours daily.
On 11/6/18 from 9:50 AM to 10:39 AM, Resident #30 was observed sitting in his Broda chair (tilt-in-space positioning chair) asleep and snoring. Resident 30 was observed asleep in his Broda chair on 11/6/18 at 2:28 PM, 11/7/18 at 11:00 AM and 4:20 PM, and 11/8/18 at 7:00 AM.
On 11/9/18 at 9:56 AM, LMSW #1 stated Resident #30's specific behavior was wandering into other residents' rooms. LMSW #1 stated Resident #30's dementia presented as confusion and increased anxiety. LMSW #1 stated Resident #30 should have a care plan for anxiety and his dementia care plan should describe how his behaviors presented. LMSW #1 stated missing information in Resident #30's care plan made it difficult for contracted agency staff to observe for those behaviors and document them.
c. Resident #2 was readmitted to the facility on [DATE], with multiple diagnoses including insomnia, dementia, PTSD (post-traumatic stress disorder), anxiety, depression, and Alzheimer's disease.
Resident #2's quarterly MDS assessment, dated 7/21/18, documented his cognition was severely impaired, and family or representative participated in the assessment. The MDS documented Resident #2 received antipsychotic and antidepressant medications on a routine basis and documented target behaviors. The MDS target behaviors included delusions, physical, verbal, and other behaviors 1-3 days a week.
Resident #2's care plan related to his behavior and mood, dated 5/3/17, did not identify resident specific behaviors or include interventions related to Resident #2's depression, PTSD, and anxiety. The care plan included Resident #2's dementia, dated 2/20/18, but did not document how his dementia presented or interventions related to the dementia.
Resident #2's physician's orders, included Escitalopram Oxalate (antidepressant) 10 mg by mouth one time a day for depression/PTSD, ordered on 4/3/18; Risperdal 1 mg by mouth two times a day for unstable mood, ordered on 8/9/18; and Trazadone HCl 100 mg by mouth at bedtime for insomnia, ordered on 11/2/18. The orders included monitoring the number of hours of sleep every shift for insomnia, and to observe Resident #2 for side effects every shift related to the use of antidepressant and antipsychotic medications.
Resident #2's Quarterly Mood/Behavior Medication Review, dated 8/7/18, listed his diagnoses for dementia and depression, it did not include his diagnoses for anxiety and PTSD. The review included a section for antidepressant medications and the date initiated. Under this section Escitalopram Oxalate and Trazadone were listed. The review documented Trazadone was used for anxiety and insomnia. Under another section for antipsychotic medications Risperdal was listed. The Trazadone was indicated for insomnia not anxiety according to his physician orders.
The Quarterly Review documented Resident #2 had an increase in aggression directed toward other residents and staff over the past few weeks. There was no documentation how it was determined his aggression increased. The Quarterly Review documented the IDT was unable to determine other causes for Resident #2's increased aggression beyond dementia and psychosis. Resident #2's record did not include a diagnosis of psychosis.
Resident #2's Behavior and Mood Monitoring Flowsheets, dated 10/1/18 through 11/8/18, monitored each shift for general behaviors and mood symptoms. The flowsheets included a section for response to interventions and effectiveness of the interventions, but they were not specific to Resident #2. The flowsheets did not document the effectiveness of Resident #2's use of psychotropic medications and did not identify the behaviors to monitor related to the use of psychotropic medications.